rss
Br J Ophthalmol 2004;88:1100-1101 doi:10.1136/bjo.2004.043406
  • Letter

Sequential treatment of central retinal vein occlusion with intravitreal tissue plasminogen activator and intravitreal triamcinolone

  1. J M L1,
  2. J J K1,2,
  3. M C Cheung1,
  4. J M Lahey2
  1. 1Ophthalmology, University of California at San Francisco, San Francisco, CA, USA
  2. 2Ophthalmology, Kaiser Permanente, Hayward, CA, USA
  1. Correspondence to: J M Lahey MD Ophthalmology (Retina), Kaiser Permanente Medical Center, 27400 Hesperian Boulevard, Hayward, CA 94545-4299, USA; Mike.Laheykp.org
  • Accepted 3 February 2004

Treatment for central retinal vein occlusion (CRVO) remains disappointing despite recently proposed intraocular surgical techniques.1,2 We previously introduced the use of intravitreal tissue plasminogen activator (TPA) for acute central retinal vein occlusion in 1999.3 Numerous investigators have confirmed its safety and suggested that it may have a beneficial role in the treatment of acute central retinal vein occlusion.4–7 Although some studies in rabbits suggest the rabbit retina is not permeable to TPA, investigators found the porcine retina was, in fact, permeable to TPA.8,9 Our clinical experience with intravitreal TPA in humans with CRVO and large submacular haemorrhages strongly suggests that intravitreal TPA does cross the …

[Full text of this article]

This Article

  1. Extract
  2. Full text
  3. PDF

Responses

  1. Submit a response
  2. No responses published

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.